Parkes, Joanna E; Boehler, Jessica F; Li, Ning; Kendra, Ryan M; O'Hanlon, Terrance P; Hoffman, Eric P; Peterson, Jennifer M; Miller, Frederick W; Rider, Lisa G; Nagaraju, Kanneboyina
description
The B-cell depleting biologic, rituximab, is used to treat refractory autoimmune myositis. However, the beneficial effects of rituximab appear to outweigh the known contribution of B cells in myositis. We aimed to elucidate how myositis patients respond differently to rituximab and possible alternative mechanisms of action.
